close

Agreements

Date: 2011-04-21

Type of information: Licensing agreement

Compound: Eyeprim® device

Company: Iris Pharma (France) OPIA Technologies (France)

Therapeutic area: Ophtalmology

Type agreement:

Licensing
Development

Action mechanism:

Eyeprim® is a patented sampling device used to perform conjunctival impressions. The conjunctival impression technique allows the most superficial layer of the conjunctival epithelial cells (both goblet and non-goblet cells) to be collected from the conjunctival mucosa in a quasi-painless and non-invasive way, for the purpose of analyses and diagnosis.

Disease:

Details:

Iris Pharma and OPIA Technologies have entered into a long-term licence agreement for the development of Eyeprim®, OPIA's main device platform, in animal studies. As part of the agreement, Iris Pharma will obtain the exclusive licence for the use of Eyeprim® device to perform ocular surface biopsies of the living eye in its preclinical research activities. Eyeprim® is a patented sampling device platform to perform conjunctival impressions. This device should become a diagnostic test template in the near future. Founded in january 2010 and based at the new Vision Institute in Paris, OPIA Technologies is a company dedicated to the development of innovative medical devices for ophtalmology, from prototyping to industrialization.

Financial terms:

Latest news:

Is general: Yes